Close Menu

NEW YORK – German rare disease company Centogene on Thursday reported a 13 percent year-over-year revenue decrease in Q3 caused mainly by non-recurring upfront payments by two pharmaceutical partners a year ago.

"We're driving solid performance that is much better than what it might appear on paper," said Centogene CEO Arndt Rolfs during a conference call to discuss the financial results.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.